Roth Capital Gives Phibro Animal Health Positive Coverage
December 22, 2022
Trending News ☀️
PAHC Intrinsic Value – Phibro Animal Health ($NASDAQ:PAHC) Corporation is a leading global diversified animal health and nutrition company that develops, manufactures, and markets products and services for the poultry, swine, cattle, aquaculture, and pet food markets. Analysts at Roth Capital have recently given Phibro Animal Health new coverage, and their opinion is generally positive. They believe that the company’s strong presence in the animal health industry, and its diverse product portfolio, will provide a platform for long-term growth. Roth Capital also believes that the company’s investment in research and development will allow it to capitalize on emerging trends in the animal health industry. Roth Capital also believes that Phibro Animal Health’s financials are strong, with high margins and low debt levels. They believe that the company has a solid balance sheet that provides a cushion for potential losses in the future.
In addition, they expect the company’s revenue to grow significantly over the next few years as they continue to expand their product offerings. Roth Capital is optimistic about the outlook for Phibro Animal Health. They believe that the company is well-positioned to capitalize on the growth of the animal health industry. They also believe that the company’s diversified product portfolio will provide a platform for long-term growth and success.
Share Price
On Wednesday, the PHIBRO ANIMAL HEALTH stock opened at $13.4 and closed at $13.7, a 7.2% rise from its last closing price of 12.8. The company seems to be doing well, with its share price increasing steadily since the start of the year. Analysts at the firm have already given the company a ‘buy’ rating and are optimistic about its potential for growth in the future. This is good news for investors who may be looking to increase their holdings in the company. Roth Capital’s coverage is a great vote of confidence for Phibro Animal Health and shows that the analysts are bullish on the company’s prospects.
This is good news for the company, as it will likely attract more investors who are looking to take advantage of the potential for growth that the company has to offer. Overall, Roth Capital’s positive coverage of Phibro Animal Health is a good sign for the company and could be indicative of better things to come. The company’s share price has been steadily increasing since the start of the year and this could be just the beginning. Investors may want to keep an eye on this stock as it could be a great long-term investment opportunity. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for PAHC. More…
| Total Revenues | Net Income | Net Margin |
| 960.12 | 46.5 | 4.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for PAHC. More…
| Operations | Investing | Financing |
| 17.13 | -18.07 | 37.4 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for PAHC. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 948.38 | 685.62 | 6.49 |
Key Ratios Snapshot
Some of the financial key ratios for PAHC are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.5% | 3.4% | 8.4% |
| FCF Margin | ROE | ROA |
| -3.7% | 19.3% | 5.3% |
VI Analysis – PAHC Intrinsic Value Calculator
PHIBRO ANIMAL HEALTH’s fundamentals provide an insight into its long term potential, which can be easily evaluated with the VI app. According to the analysis by VI Line, PHIBRO ANIMAL HEALTH’s intrinsic value is estimated to be at around $23.8, but it is currently being traded at $13.7, implying a 43% undervaluation. This makes it an attractive option for investors who are looking for good returns. The company has a consistent history of profitability and has been able to maintain a steady growth rate over the years. It has a strong balance sheet, low debt levels, and a healthy cash flow. Furthermore, its strong market position is likely to ensure that the company continues to perform well in the future. In conclusion, PHIBRO ANIMAL HEALTH is an attractive investment opportunity due to its high intrinsic value and current undervaluation. More…
VI Peers
Phibro Animal Health Corp and its competitors, Rhone Ma Holdings Bhd, BioGaia AB, and Elanco Animal Health Inc, are all vying for a share of the animal health market. The competition is fierce, but Phibro is confident in its products and is determined to maintain its position as a leader in the industry.
– Rhone Ma Holdings Bhd ($KLSE:5278)
Rhone Ma Holdings Bhd is a Malaysian conglomerate with interests in property development and investment, construction, and hotel ownership and operation. The company has a market capitalization of 153.75 million as of 2022 and a return on equity of 8.81%. Rhone Ma Holdings is headquartered in Kuala Lumpur and was founded in 1965.
– BioGaia AB ($LTS:0GTN)
Biogaia is a Swedish biotech company that focuses on developing and commercializing probiotics. The company’s products are based on the naturally occurring Lactobacillus reuteri bacteria, which has been shown to have numerous health benefits. Biogaia’s products are available in over 60 countries and are sold in a variety of forms, including capsules, tablets, sachets, and powder.
– Elanco Animal Health Inc ($NYSE:ELAN)
Elanco Animal Health Inc is a animal health company that develops, manufactures, and markets products for both food and companion animals. The company has a market cap of 5.81B as of 2022 and a return on equity of 0.31%. Elanco’s products include antibiotics, vaccines, and parasiticides. The company’s products are sold in over 90 countries around the world.
Summary
Investing in Phibro Animal Health can be a great opportunity for those looking to diversify their portfolio. The company has a long history of success and is a leader in the animal health industry. They offer a variety of products and services that benefit both animals and their owners. The company’s stock price has been steadily increasing over the last few years, and their recent positive coverage from Roth Capital has only further boosted investor confidence in the company. Phibro Animal Health is a great choice for investors who are looking to invest in a company with a track record of success and a bright outlook. The company has experienced steady growth in sales over the past few years, and they have been able to successfully expand into new markets. The company has also been able to remain competitive within the industry by continually innovating and improving their products and services. The company has also put significant resources into research and development, which has resulted in the development of new products and services for animals. This has allowed the company to remain competitive and keep up with the ever-changing animal health industry.
Additionally, the company has an impressive portfolio of patents, which provides them with an additional edge over their competitors. Overall, investing in Phibro Animal Health can be a great opportunity for investors looking to diversify their portfolio and benefit from the company’s strong track record of success. With their recent positive coverage from Roth Capital, the stock price is likely to continue to increase, making the company an attractive investment.
